Centro de Imagem Diagnósticos S.A (AALR3) - Net Assets
Based on the latest financial reports, Centro de Imagem Diagnósticos S.A (AALR3) has net assets worth R$1.10 Billion BRL (≈ $215.70 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (R$3.03 Billion ≈ $594.03 Million USD) and total liabilities (R$1.93 Billion ≈ $378.33 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check AALR3 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | R$1.10 Billion |
| % of Total Assets | 36.31% |
| Annual Growth Rate | 28.05% |
| 5-Year Change | -7.1% |
| 10-Year Change | 55.09% |
| Growth Volatility | 161.69 |
Centro de Imagem Diagnósticos S.A - Net Assets Trend (2010–2024)
This chart illustrates how Centro de Imagem Diagnósticos S.A's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Centro de Imagem Diagnósticos S.A for the complete picture of this company's asset base.
Annual Net Assets for Centro de Imagem Diagnósticos S.A (2010–2024)
The table below shows the annual net assets of Centro de Imagem Diagnósticos S.A from 2010 to 2024. For live valuation and market cap data, see Centro de Imagem Diagnósticos S.A market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | R$1.14 Billion ≈ $223.06 Million |
+20.43% |
| 2023-12-31 | R$943.99 Million ≈ $185.23 Million |
-3.86% |
| 2022-12-31 | R$981.92 Million ≈ $192.67 Million |
-18.81% |
| 2021-12-31 | R$1.21 Billion ≈ $237.31 Million |
-1.16% |
| 2020-12-31 | R$1.22 Billion ≈ $240.11 Million |
-7.30% |
| 2019-12-31 | R$1.32 Billion ≈ $259.01 Million |
+1.56% |
| 2018-12-31 | R$1.30 Billion ≈ $255.03 Million |
+2.32% |
| 2017-12-31 | R$1.27 Billion ≈ $249.25 Million |
+4.81% |
| 2016-12-31 | R$1.21 Billion ≈ $237.80 Million |
+65.34% |
| 2015-12-31 | R$733.00 Million ≈ $143.83 Million |
-1.39% |
| 2014-12-31 | R$743.32 Million ≈ $145.85 Million |
+165.96% |
| 2013-12-31 | R$279.49 Million ≈ $54.84 Million |
+18.97% |
| 2012-12-31 | R$234.93 Million ≈ $46.10 Million |
-8.64% |
| 2011-12-31 | R$257.14 Million ≈ $50.46 Million |
+621.00% |
| 2010-12-31 | R$35.66 Million ≈ $7.00 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Centro de Imagem Diagnósticos S.A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 63497400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | R$612.41 Million | 55.94% |
| Other Comprehensive Income | R$1.12 Billion | 102.23% |
| Total Equity | R$1.09 Billion | 100.00% |
Centro de Imagem Diagnósticos S.A Competitors by Market Cap
The table below lists competitors of Centro de Imagem Diagnósticos S.A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vytrus Biotech S.A.
MC:VYT
|
$88.79 Million |
|
LumenRadio AB
ST:LUMEN
|
$88.82 Million |
|
Toma as
PR:TOMA
|
$88.82 Million |
|
Elite Naturel Organik Gida Sanayi ve Ticaret AS
IS:ELITE
|
$88.82 Million |
|
Big River Industries Ltd
AU:BRI
|
$88.64 Million |
|
Naim Holdings Bhd
KLSE:5073
|
$88.63 Million |
|
Shinhung
KO:004080
|
$88.63 Million |
|
Evergreen Max Cash Capital Berhad
KLSE:0286
|
$88.61 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Centro de Imagem Diagnósticos S.A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 917,456,000 to 1,094,793,000, a change of 177,337,000 (19.3%).
- Net loss of 129,119,000 reduced equity.
- Share repurchases of 310,900,000 reduced equity.
- New share issuances of 310,900,000 increased equity.
- Other comprehensive income increased equity by 306,075,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | R$-129.12 Million | -11.79% |
| Share Repurchases | R$310.90 Million | -28.4% |
| Share Issuances | R$310.90 Million | +28.4% |
| Other Comprehensive Income | R$306.07 Million | +27.96% |
| Other Changes | R$381.00K | +0.03% |
| Total Change | R$- | 19.33% |
Book Value vs Market Value Analysis
This analysis compares Centro de Imagem Diagnósticos S.A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.32x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.62x to 0.32x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | R$4.78 | R$2.97 | x |
| 2013-12-31 | R$5.43 | R$2.97 | x |
| 2014-12-31 | R$13.02 | R$2.97 | x |
| 2015-12-31 | R$7.79 | R$2.97 | x |
| 2016-12-31 | R$11.60 | R$2.97 | x |
| 2017-12-31 | R$10.41 | R$2.97 | x |
| 2018-12-31 | R$10.60 | R$2.97 | x |
| 2019-12-31 | R$10.87 | R$2.97 | x |
| 2020-12-31 | R$10.09 | R$2.97 | x |
| 2021-12-31 | R$10.00 | R$2.97 | x |
| 2022-12-31 | R$8.06 | R$2.97 | x |
| 2023-12-31 | R$7.76 | R$2.97 | x |
| 2024-12-31 | R$9.21 | R$2.97 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Centro de Imagem Diagnósticos S.A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -11.79%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -10.61%
- • Asset Turnover: 0.42x
- • Equity Multiplier: 2.64x
- Recent ROE (-11.79%) is below the historical average (-3.15%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 12.27% | 15.48% | 0.56x | 1.41x | R$5.28 Million |
| 2013 | 10.15% | 10.03% | 0.47x | 2.16x | R$410.90K |
| 2014 | -0.57% | -1.06% | 0.27x | 1.99x | R$-77.74 Million |
| 2015 | -1.78% | -1.82% | 0.46x | 2.15x | R$-84.37 Million |
| 2016 | 1.26% | 1.55% | 0.44x | 1.85x | R$-102.57 Million |
| 2017 | 0.55% | 0.62% | 0.47x | 1.87x | R$-115.29 Million |
| 2018 | 3.19% | 3.72% | 0.49x | 1.76x | R$-85.61 Million |
| 2019 | 3.22% | 3.85% | 0.45x | 1.87x | R$-86.92 Million |
| 2020 | -8.18% | -10.49% | 0.37x | 2.13x | R$-216.47 Million |
| 2021 | -0.48% | -0.49% | 0.45x | 2.16x | R$-123.15 Million |
| 2022 | -23.99% | -21.00% | 0.41x | 2.75x | R$-322.78 Million |
| 2023 | -24.84% | -19.32% | 0.44x | 2.91x | R$-319.62 Million |
| 2024 | -11.79% | -10.61% | 0.42x | 2.64x | R$-238.60 Million |
Industry Comparison
This section compares Centro de Imagem Diagnósticos S.A's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $2,596,908,500
- Average return on equity (ROE) among peers: 6.01%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Centro de Imagem Diagnósticos S.A (AALR3) | R$1.10 Billion | 12.27% | 1.75x | $88.77 Million |
| Diagnósticos da América S.A (DASA3) | $97.55 Million | 0.00% | 0.62x | $828.87 Million |
| Fleury S.A. (FLRY3) | $5.10 Billion | 12.03% | 1.59x | $1.72 Billion |
About Centro de Imagem Diagnósticos S.A
Alliança Saúde e Participações S.A. provides diagnostic imaging and medicine services in Brazil. The company offers diagnostic imaging, clinical analysis, nuclear medicine, genetic testing, and vaccination services, as well as corporate, remote, and in-person solutions for hospitals and diagnostic centers in the private and public sectors. It provides clinical analysis services, such as blood cou… Read more